Dr. Patrick Gray reports
PASCAL BIOSCIENCES ANNOUNCES LISTING ON THE FRANKFURT STOCK EXCHANGE
Pascal Biosciences Inc.'s common shares were accepted for listing on the Frankfurt Stock Exchange under the trading symbol 6PB, ISIN: CA7024781089, WKN: A2DQU4. The company's common shares are now cross-listed on the TSX Venture Exchange and the FSE.
"We are very pleased to have Pascal shares listed on the Frankfurt Stock Exchange," said Dr. Patrick Gray, chief executive officer of Pascal. "This listing will offer a large number of new investors the opportunity to invest in Pascal, expanding our shareholder base and potentially increasing liquidity."
The Frankfurt Stock Exchange is one of the world's leading international stock exchanges by revenue, profitability and market capitalization. The FSE provides access to millions of international investors, and only Nasdaq and the New York Stock Exchanges are larger. An FSE listing is expected to increase trading liquidity, and can assist in attracting investment by institutional and retail investors in Europe.
About Pascal Biosciences Inc.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics.